Amyloid Beta Peptides in Blood Plasma Are Viable Biomarkers of Alzheimer’s, Study Reports

Amyloid Beta Peptides in Blood Plasma Are Viable Biomarkers of Alzheimer’s, Study Reports
A study by researchers at the Centre for Healthy Brain Ageing (CHeBA) detailed, reportedly for a first time, the relationship between plasma levels of two types of amyloid beta peptides and cognitive function and brain volume, factors known to be diminished in Alzheimer’s disease (AD). The findings suggested that blood plasma measures of such peptides constitute an easy-to-collect and viable biomarker for a risk analysis or early diagnosis of the disease. The study, “The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study,” was published in
Subscribe or to access all post and page content.